ASH 2019: Initial results of a phase II study investigating Vemurafenib combined with Obinutuzumab for first line treatment of Hairy Cell leukemia.
Home / Resource Library / First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl